Top Markets
#1 Akedo Akedo +54.06%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.26%
#4 Cross Cross +47.18%
#5 Black Phoenix Black Phoenix +34.15%
#6 Velvet Velvet +31.77%
#7 OVERTAKE OVERTAKE +18.70%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.05%
#9 Movement Movement +13.43%
#10 Perle Perle +11.98%
Coin of the day
Akedo Akedo
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

BLCM
Kedudukan dalam Saham #38880
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage... Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.
Harga Saham
$0.07475
Disegerakkan terakhir: 2024-03-04
Modal Pasaran
$755.60K
Perubahan (1 hari)
-6.68%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Bellicum Pharmaceuticals, Inc. (BLCM)

Kategori

Healthcare
Nisbah P/E bagi Bellicum Pharmaceuticals, Inc. (BLCM)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Bellicum Pharmaceuticals, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Bellicum Pharmaceuticals, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.